RxDoctor Payments DataLook up a doctor →

Jian Pang, MD

Endocrinology, Diabetes & Metabolism · Newnan, GANPI 1558637058

Payments from drug & device makers

$10,467in general payments, 2019–2025

Across 435 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Novo Nordisk$1K
  • Abbott$1K
  • Lilly USA, LLC$909
  • IBSA Pharma Inc.$642
  • Xeris Pharmaceuticals, Inc.$600
  • plus $5K from 39 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)30$1,462
Novo Nordisk53$1,159
Abbott54$1,015
Lilly USA, LLC33$909
IBSA Pharma Inc.30$642
Xeris Pharmaceuticals, Inc.27$600
Radius Health, Inc.21$458
Bayer18$404
Corcept Therapeutics13$343
Boehringer Ingelheim16$311
AstraZeneca(2 entities)17$281
Mannkind Corporation8$232
AbbVie13$215
Sanofi-aventis U.S. LLC13$214
Amgen(2 entities)10$185
Tandem Diabetes Care, Inc.9$185
Astellas Pharma US Inc4$178
BETA Bionics, Inc.5$165
Insulet Corporation7$141
Dexcom, Inc.7$135
Calliditas Therapeutics US Inc.1$133
Amneal Pharmaceuticals LLC7$131
Cequr Corporation2$131
Lundbeck LLC1$125
Recordati_rare_diseases_inc.3$85
Amarin Pharma, Inc.3$61
Merck3$52
Johnson & Johnson3$44
Shire North American Group Inc2$43
Esperion Therapeutics, Inc.3$42
EMD Serono, Inc.1$41
Sequel Med Tech, LLC2$39
Sandoz1$34
Ascendis Pharma Endocrinology Inc2$32
Antares Pharma, Inc.2$32
Companion Medical, Inc.2$31
GRT US Holding, Inc.1$25
EUSA Pharma (US) LLC1$24
Amryt Pharma Holdings Ltd1$24
Ultragenyx Pharmaceutical Inc.1$21
Exact Sciences1$21
Nevro Corp.1$17
Rhythm Pharmaceuticals, Inc.1$15
Echosens North America, Inc.1$15
Halozyme Inc1$14

How this compares

$10,467 in reported general payments places this provider in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024
$56,628
Medicare patients
99
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Newnan

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →